Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 11/20 | 0.62 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.62 |
| ▸ | NOS2 | P35228 | 2/20 | 0.53 |
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3860789 | 1.00 | BHMT (0.62) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL19346123 | 0.84 | ARG1 (0.51) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL21851894 | 0.81 | BHMT (0.76) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL27791649 | 0.81 | BHMT (0.76) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL1031686 | 0.81 | BHMT (0.76) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL1031684 | 0.81 | BHMT (0.76) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL19800803 | 0.80 | BHMT (0.72) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL19800800 | 0.80 | BHMT (0.72) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL28352319 | 0.79 | TSHR (0.62) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL28352320 | 0.79 | TSHR (0.62) | BHMTBHMT2NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107427576-A | Dosing regimens for MAdCAM antagonists | 辉瑞公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-105873943-A | Fusion proteins | 利维塞普特有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-7547714-B2 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4 beta ,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; glucocorticoid receptor modulators; antiinflammatory agents; Alzheimer's disease | PFIZER, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080312294-A1 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4 beta ,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; glucocorticoid receptor modulators; antiinflammatory agents; Alzheimer's disease; side effect reduction | PFIZER, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| CN-101065355-A | N- [ (3s)- pyrrolidin-3-yl]- benzamide derivatives as monoamine re-uptake inhibitors | PFIZER (US) | 2007-10-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312294-A1 | (4 beta S,7R,8 alpha R)-4 beta -benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4 beta ,5,6,7,8,8 alpha ,9,10-octahydrophenanthrene-2-carboxamide; glucocorticoid receptor modulators; antiinflammatory agents; Alzheimer's disease; side effect reduction | NR3C1, NR3C2, MC2R | BHMT 874/4885BHMT2 695/4885NOS2 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.